Different benefits of adaptive radiotherapy for different histologies of NSCLC

References

• WHO.int [Internet]. Geneva (Switzerland): WHO; 2023 [cited 2023 Feb 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• Travis WD, Brambilla E, Nicholson AG, WHO Panel, et al. The 2015 World Health Organization classification of lung tumors. J Thorac Oncol. 2015;10(9):1243–1260. doi: 10.1097/JTO.0000000000000630.
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Adjei AA, et al. Non–small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594. doi: 10.4065/83.5.584.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi: 10.1038/nature25183.
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640. doi: 10.1016/j.mayocp.2019.01.013.
   PubMed Web of Science ®Google Scholar
• Evison M, on behalf of AstraZeneca UK Limited. The current treatment landscape in the UK for stage III NSCLC. Br J Cancer. 2020;123(Suppl 1):3–9. doi: 10.1038/s41416-020-01069-z.
   PubMed Web of Science ®Google Scholar
• Marcussen N, Sørensen FB, Steiniche T, et al. Patologi. 1st ed. Roskilde (Denmark). FADLs Forlag; 2010.
   Google Scholar
• Wang B-Y, Huang J-Y, Cheng Y-F, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol. 2020;146(1):43–52. doi: 10.1007/s00432-019-03079-8.
   PubMed Web of Science ®Google Scholar
• Relli V, Trerotola M, Alberti S, et al. Abandoning the notion of Non-Small cell lung cancer. Trends Mol Med. 2019;25(7):585–594. doi: 10.1016/j.molmed.2019.04.012.
   PubMed Web of Science ®Google Scholar
• Giraud P, Antoine M, Touboul E, et al. Evaluation of microscopic tumor extension in non–small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000;48(4):1015–1024. doi: 10.1016/S0360-3016(00)00750-1.
   PubMed Web of Science ®Google Scholar
• Nygård L, Vogelius IR, Bentzen SM, et al. A competing risk model of first failure site after definitive chemoradiation therapy for locally advanced Non-Small cell lung cancer. J Thorac Oncol. 2018;13(4):559–567. doi: 10.1016/J.JTHO.2017.12.011.
   PubMed Web of Science ®Google Scholar
• Katagiri Y, Jingu K, Kadoya N, et al. Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer. Jpn J Radiol. 2021;39(6):611–617. doi: 10.1007/s11604-021-01091-y.
   PubMed Web of Science ®Google Scholar
• Møller DS, Holt MI, Hoffmann L, et al. Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. Radiother Oncol. 2016;121(1):32–38. doi: 10.1016/j.radonc.2016.08.019.
   PubMed Web of Science ®Google Scholar
• Møller DS, Lutz CM, Hoffmann L, et al. Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. Radiother Oncol. 2022;168:234–240. doi: 10.1016/j.radonc.2022.01.039.
   PubMed Web of Science ®Google Scholar
• Boejen A, Vestergaard A, Grau C, et al. A learning programme qualifying radiation therapists to manage daily online adaptive radiotherapy. Acta Oncol. 2015;54(9):1697–1701. doi: 10.3109/0284186X.2015.1062914.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Spigel DR, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi: 10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Faivre-Finn C, Antonia SJ, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. J Clin Oncol. 2022;40(12):1301–1311. doi: 10.1200/JCO.21.01308.
   PubMed Web of Science ®Google Scholar
• Kelsey CR, Marks LB, Boyd JA, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009;115(22):5218–5227. doi: 10.1002/cncr.24625.
   PubMed Web of Science ®Google Scholar
• Woody NM, Stephans KL, Abazeed ME, et al. A histologic basis for the efficacy of SBRT to the lung. J Thorac Oncol. 2017;12(3):510–519. doi: 10.1016/j.jtho.2016.11.002.
   PubMed Web of Science ®Google Scholar
• Hörner-Rieber J, Bernhardt D, Rieken S, et al. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. Radiother Oncol. 2017;125(2):317–324. doi: 10.1016/j.radonc.2017.08.029.
   PubMed Web of Science ®Google Scholar
• Defraene G, Dankers FJWM, Ruysscher DD, et al. Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer. Radiother Oncol. 2020;152:117–125. doi: 10.1016/j.radonc.2019.09.005.
   PubMed Web of Science ®Google Scholar
• Pan L, Lei D, Wang D, et al. Heart dose linked with cardiac events and overall survival in lung cancer radiotherapy: a meta-analysis. Medicine. 2020;99(38):e21964. doi: 10.1097/MD.0000000000021964.
   PubMed Web of Science ®Google Scholar
• Hansen O, Knap MM, Schytte T, et al. A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60 Gy and 66 Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. Radiother Oncol. 2017;123(2):276–281. doi: 10.1016/j.radonc.2017.03.017.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Garon EB, Baas P, et al. Five year survival update From KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1–positive advanced NSCLC. J Thorac Oncol. 2021;16(10):1718–1732. doi: 10.1016/j.jtho.2021.05.001.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Gettinger S, Brahmer J, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer. J Clin Oncol. 2021;39(7):723–733. doi: 10.1200/JCO.20.01605.
   PubMed Web of Science ®Google Scholar
• Dupic G, Biau J, Bellière-Calandry A, et al. Significant correlation between overall survival and mean lung dose in lung stereotactic body radiation therapy (SBRT). Front Oncol. 2020;10:1577. doi: 10.3389/fonc.2020.01577.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Choy H, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–199. doi: 10.1016/S1470-2045(14)71207-0.
   PubMed Web of Science ®Google Scholar